RLMD - Relmada Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
6/29/2019
6/29/2018
6/29/2017
6/29/2016
Total Revenue
0
0
0
0
0
Cost of Revenue
-
-
-
-
-
Gross Profit
-
-
-
-
-
Operating Expenses
Research Development
7,491
7,025
2,943
1,293
6,207
Selling General and Administrative
6,533
5,703
3,975
5,925
10,009
Total Operating Expenses
14,024
12,728
6,917
7,219
16,216
Operating Income or Loss
-14,024
-12,728
-6,917
-7,219
-16,216
Interest Expense
-
-
1,337
-
-
Total Other Income/Expenses Net
-
-3,829
-707
933
13,239
Income Before Tax
-17,607
-17,318
-8,961
-6,287
-2,975
Income Tax Expense
-
-
-
-
-
Income from Continuing Operations
-17,607
-17,318
-8,961
-6,287
-2,975
Net Income
-17,607
-17,318
-8,961
-6,287
-2,975
Net Income available to common shareholders
-17,607
-17,318
-8,961
-6,287
-2,975
Reported EPS
Basic
-
-2.76
-2.84
-2.08
-1.04
Diluted
-
-2.76
-2.84
-2.08
-1.04
Weighted average shares outstanding
Basic
-
6,312
3,136
3,019
2,900
Diluted
-
6,312
3,136
3,019
2,900
EBITDA
-
-12,723
-6,915
-7,134
-16,161